The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Update on Phase I/II study of azacitidine, venetoclax and gilteritinib in patients with FLT3+ AML
Farhad Ravandi, MD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines updated results from a Phase I/II study evaluating the triplet regimen of azacitidine, venetoclax and gilteritinib in elderly and unfit patients with newly diagnosed or relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML). Overall, the novel combination was shown to be effective in the frontline setting for patients with FLT3-mutated AML, achieving high response rates (RR) that were durable. Dr Ravandi also anticipates that in the future, this novel regimen could be used for younger patients with FLT3-mutated AML to achieve remission before proceeding to allogeneic stem cell transplantation. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Xencor: Research Funding; Prelude: Research Funding; Astex/Taiho: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; AstraZeneca: Consultancy; Amgen: Honoraria, Research Funding; Novartis: Consultancy; BMS/Celgene: Consultancy, Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Syos: Consultancy, Honoraria, Research Funding; Astellas: Consultancy, Honoraria, Research Funding; Biomea Fusion, Inc.: Research Funding.
